{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:09:34Z","timestamp":1788869374861,"version":"build-2803163510"},"reference-count":21,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100006062","name":"Foundation for Promotion of Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancergeneticsjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Genetics and Cytogenetics"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1016\/j.cancergencyto.2008.04.021","type":"journal-article","created":{"date-parts":[[2008,9,10]],"date-time":"2008-09-10T06:34:24Z","timestamp":1221028464000},"page":"6-11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Recurrent der(9;18) in essential thrombocythemia with JAK2 V617F is highly linked to myelofibrosis development"],"prefix":"10.1016","volume":"186","author":[{"given":"Kazuma","family":"Ohyashiki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko H.","family":"Ohyashiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cancergencyto.2008.04.021_bib1","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.cancergencyto.2008.04.021_bib2","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.cancergencyto.2008.04.021_bib3","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cancergencyto.2008.04.021_bib4","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cancergencyto.2008.04.021_bib5","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1074\/jbc.C500138200","article-title":"Identification of an acquired JAK2 mutation in polycythemia vera","volume":"280","author":"Zhao","year":"2005","journal-title":"J Biol Chem."},{"key":"10.1016\/j.cancergencyto.2008.04.021_bib6","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1056\/NEJMp058083","article-title":"A unifying mutation in chronic myeloproliferative disorders","volume":"352","author":"Goldman","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cancergencyto.2008.04.021_bib7","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1182\/blood-2007-08-107748","article-title":"Ratio of mutant JAK2-V617F to wild type JAK2 determines the MPD phenotypes in transgenic mice","volume":"111","author":"Tiedt","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.cancergencyto.2008.04.021_bib8","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.leu.2405043","article-title":"Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F","volume":"22","author":"Shide","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.cancergencyto.2008.04.021_bib9","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/sj.leu.2404604","article-title":"JAK2V617F mutational status as determined by semiquantitative sequence-specific primer-single molecule fluorescence detection assay is linked to clinical features in chronic myeloproliferative disorders","volume":"21","author":"Ohyashiki","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.cancergencyto.2008.04.021_bib10","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/sj.leu.2404666","article-title":"Thrombosis can occur at any phase of essential thrombocythemia with JAK2V617F mutation: a single institutional study in Japan","volume":"21","author":"Ohyashiki","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.cancergencyto.2008.04.021_bib11","series-title":"World Health Organization of Tumours: Pathology and Genetics of Tumours of Hematopoietic and Lymphoid Tissues","first-page":"39","article-title":"Essential thrombocythemia","author":"Imbert","year":"2001"},{"key":"10.1016\/j.cancergencyto.2008.04.021_bib12","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.cancergencyto.2007.07.008","article-title":"Automated JAK2V617F quantification using a magnetic filtration system and sequence-specific primer-single molecule fluorescence detection","volume":"179","author":"Ohyashiki","year":"2007","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.cancergencyto.2008.04.021_bib13","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.leukres.2005.03.011","article-title":"De novo appearance of der(1;7)(q10;p10) is associated with leukemic transformation and unfavorable prognosis in essential thrombocythemia","volume":"29","author":"Hsiao","year":"2005","journal-title":"Leuk Res"},{"key":"10.1016\/j.cancergencyto.2008.04.021_bib14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1600-0609.1984.tb02204.x","article-title":"Abnormalities of chromosome 13 in myelofibrosis","volume":"33","author":"Borgstr\u00f6m","year":"1984","journal-title":"Scand J Haematol"},{"key":"10.1016\/j.cancergencyto.2008.04.021_bib15","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cancergencyto.2006.09.021","article-title":"Cytogenetics of agnogenic myeloid metaplasia: a study of 61 patients","volume":"173","author":"Djordjevic","year":"2007","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.cancergencyto.2008.04.021_bib16","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S0165-4608(02)00678-7","article-title":"Karyotypic abnormalities in myelofibrosis following polycythemia vera","volume":"140","author":"Andrieux","year":"2003","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.cancergencyto.2008.04.021_bib17","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0025-6196(12)61011-8","article-title":"Chromosome studies in 104 patients with polycythemia vera","volume":"66","author":"Diez-Martin","year":"1991","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.cancergencyto.2008.04.021_bib18","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0165-4608(87)90183-X","article-title":"A chromosomal profile of polycythemia vera","volume":"25","author":"Rege-Cambrin","year":"1987","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.cancergencyto.2008.04.021_bib19","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cancergencyto.2003.09.011","article-title":"Is fluorescence in situ hybridization a useful method in diagnosis of polycythemia vera patients?","volume":"151","author":"Zamora","year":"2004","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.cancergencyto.2008.04.021_bib20","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.cancergencyto.2006.09.015","article-title":"A der(18) t(9;18)(p13;p11) and a der(9;18)(p10;q10) in polycythemia vera associated with a hyperproliferative phenotype in transformation to postpolycythemic myelofibrosis","volume":"172","author":"Larsen","year":"2007","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.cancergencyto.2008.04.021_bib21","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.cancergencyto.2004.12.015","article-title":"Gain of 9p due to an unbalanced rearrangement der(9;18): a recurrent clonal abnormality in chronic myeloproliferative disorders","volume":"160","author":"Bacher","year":"2005","journal-title":"Cancer Genet Cytogenet"}],"container-title":["Cancer Genetics and Cytogenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016546080800277X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016546080800277X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T10:10:01Z","timestamp":1762251001000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016546080800277X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["S016546080800277X"],"URL":"https:\/\/doi.org\/10.1016\/j.cancergencyto.2008.04.021","relation":{},"ISSN":["0165-4608"],"issn-type":[{"value":"0165-4608","type":"print"}],"subject":[],"published":{"date-parts":[[2008,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recurrent der(9;18) in essential thrombocythemia with JAK2 V617F is highly linked to myelofibrosis development","name":"articletitle","label":"Article Title"},{"value":"Cancer Genetics and Cytogenetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cancergencyto.2008.04.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}